Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
26.20
+0.24 (0.92%)
Aug 1, 2025, 4:00 PM - Market closed

R1 RCM Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
-34.77-29.4-17.35-20.54
Depreciation & Amortization
0.10.10.10.09
Loss (Gain) From Sale of Investments
-0.07--0.19-0.36
Stock-Based Compensation
0.320.320.310.25
Other Operating Activities
7.542.040.050.03
Change in Accounts Payable
3.185.57-1.012.2
Change in Other Net Operating Assets
1.863.07-2.950.47
Operating Cash Flow
-21.86-18.31-21.04-17.87
Capital Expenditures
----0.05
Investment in Securities
-10.88-22.47-21.95
Investing Cash Flow
-10.88-22.47-22
Long-Term Debt Issued
-28.3--
Net Debt Issued (Repaid)
28.328.3--
Issuance of Common Stock
00.0100
Other Financing Activities
-2.91-1.3--
Financing Cash Flow
25.392700
Net Cash Flow
-7.358.71.43-39.86
Free Cash Flow
-21.86-18.31-21.04-17.92
Free Cash Flow Per Share
-3.42-2.86-3.30-2.81
Levered Free Cash Flow
--6.91-15.13-
Unlevered Free Cash Flow
--6.91-15.13-
Change in Net Working Capital
--10.243.88-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.